Jad G. Sfeir

Jul 2, 2024 | nature.com | Joshua N Farr |Jad G. Sfeir |Dominik Saul |Kai Yu |Tamara Tchkonia |Nathan K. LeBrasseur | +2 more

AbstractPreclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss. Thus, we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women (n = 60 participants).